Mersana Therapeutics Price to Free Cash Flow Ratio 2016-2022 | MRSN

Historical price to free cash flow ratio values for Mersana Therapeutics (MRSN) since 2016. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Mersana Therapeutics Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-05-20 3.49 0.00
2022-03-31 3.99 $-1.70 0.00
2021-12-31 6.22 $-1.99 0.00
2021-09-30 9.43 $-1.75 0.00
2021-06-30 13.58 $-1.50 0.00
2021-03-31 16.18 $-1.17 0.00
2020-12-31 26.61 $-1.22 0.00
2020-09-30 18.62 $-1.25 0.00
2020-06-30 23.40 $-1.36 0.00
2020-03-31 5.83 $-1.22 0.00
2019-12-31 5.73 $-1.57 0.00
2019-09-30 1.58 $-1.88 0.00
2019-06-30 4.05 $-1.99 0.00
2019-03-31 5.26 $-2.48 0.00
2018-12-31 4.08 $-2.46 0.00
2018-09-30 10.00 $-3.95 0.00
2018-06-30 17.86 $9.88 1.81
2018-03-31 15.77 $-4.42 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.335B $0.000B
Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00
SQZ Biotechnologies (SQZ) United States $0.092B 0.00